Usage of cookies

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our Privacy policy.

Close
Skip to content

Press Release

Ascension Healthcare plc announces a positive update on its intellectual property portfolio

Key patent receives notice of no opposition from the European Patent Office

LONDON, May 14, Ascension Healthcare plc (“Ascension” or the “Company”), a clinical stage biopharmaceutical company developing and commercialising nanolipid technologies for unmet medical needs, is pleased to announce that it has received a notice of no opposition from the European Patent Office (EPO) for a key patent underlying one of its important technology platforms.

Patent EP20100742250 covers the key technology and composition of matter behind Ascension’s market disrupting Sequessome Technology that is used in the unique biolubricating Flexiseq gel. Flexiseq is clinically proven to provide a long-term, entirely drug-free solution to chronic joint pain such as osteoarthritis.

Richard Garraway, Chief Operating Officer, noted: “We were delighted when this patent was granted in Europe in July 2018. The expiry of the nine-month limit of no opposition is now a further milestone of confidence in Ascension’s technology and its application.”

Biresh Roy, Chief Executive Officer, commented: “Ascension continues to build value based upon the strength of its nanolipid platforms, both in its clinical stage haemophilia programmes and in marketed products such as Flexiseq, which is based on the technology in this patent. This notice is further proof of the extraordinary science supporting all of our products and programmes.”




About Ascension

Ascension Healthcare plc is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for the treatment of haemophilia and osteoarthritis.

The Company has three products in clinical or pre-clinical development for the treatment of Haemophilia A and also a range of internationally marketed products for osteoarthritis sufferers.

For more information please visit: https://ascension.co.uk/

For further information please contact

Ascension Healthcare plc
Biresh Roy, Chief Executive Officer
+44 (0)20 7291 5400
[email protected]

Consilium Strategic Communications
(European Media and Investor Enquiries)
Lindsey Neville, Priscila Radu
+44 (0)20 3709 5700
[email protected]

Ascension Healthcare plc
Biresh Roy, Chief Executive Officer

[email protected]
+44 (0)20 7291 5400